Skip to NavigationSkip to content

Bristol-Myers Squibb appoints Charles Bancroft acting chief financial officer

Published on: 15/01/10

Charles Bancroft has been appointed acting chief financial officer at Bristol-Myers Squibb, replacing Jean-Marc Huet who left the company at the end of 2009

Chairman and chief executive of Bristol-Myers Squibb James Cornelius said: “Jean-Marc has indicated to me his desire to return to Europe and we wish him every success.

“The board of directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet, his focus on increasing our cash position to nearly $10 billion through a series of important transactions, and his leadership of continuous improvement initiatives which have greatly accelerated our BioPharma transformation.”

His replacement, Charles Bancroft, was most recently vice president, finance for Bristol-Myers Squibb’s global biopharmaceutical business.

In his new role, Bancroft will continue to report to Lamberto Andreotti, president and chief operating officer.

Bancroft joined Bristol-Myers in 1984 and has since held positions of increasing responsibility within the finance organisation, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches